$15.0M
1 filing since 2025 · latest Equity filed
Grace Therapeutics, Inc. is a late-stage biopharmaceutical company dedicated to the development of innovative drug delivery technologies aimed at improving treatments for rare and orphan diseases. With a focus on enhancing the performance of existing therapies, the company seeks to expedite the onset of action, augment efficacy, minimize side effects, and provide more user-friendly delivery options for patients.
What sets it apart
Grace Therapeutics stands out through its commitment to addressing rare diseases with novel delivery methods that promise significant improvements in patient outcomes.
GTx-104 is an intravenous infusion specifically designed for treating aneurysmal subarachnoid hemorrhage (aSAH), a rare and life-threatening condition characterized by bleeding on the surface of the brain. This product is currently in late-stage clinical development.
